|
|
Article: New leaders at FDA could slow device approvals; A clinical trial executive says resignation of a review center head appears to indicate a desire for increased caution.(BUSINESS)
- Article from:
- Star Tribune (Minneapolis, MN)
- Article date:
- August 18, 2009
- Author:
CopyrightCOPYRIGHT 2009 Star Tribune Co. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Byline: JANET MOORE; STAFF WRITER
Linda Alexander, chief executive and founder of Golden Valley-based Alquest Inc., has some definite opinions about the machinations at the Food and Drug Administration (FDA).
No surprise -- Alquest is a contract research organization that specializes in conducting medical-device clinical trials and other support processes that help medical technology companies negotiate the FDA's often confounding approval process.
The Star Tribune asked Alexander about the latest turn at the FDA last week -- the abrupt resignation of Dr. Daniel Schultz, who headed the agency's Center for Devices and Radiological Health for the ...